ES2002089T3 - Nuevas formulaciones farmaceuticas con liberacion programada que contienen antiflogisticos. - Google Patents

Nuevas formulaciones farmaceuticas con liberacion programada que contienen antiflogisticos.

Info

Publication number
ES2002089T3
ES2002089T3 ES198787110389T ES87110389T ES2002089T3 ES 2002089 T3 ES2002089 T3 ES 2002089T3 ES 198787110389 T ES198787110389 T ES 198787110389T ES 87110389 T ES87110389 T ES 87110389T ES 2002089 T3 ES2002089 T3 ES 2002089T3
Authority
ES
Spain
Prior art keywords
new
pharmaceutical formulations
scheduled release
new pharmaceutical
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198787110389T
Other languages
English (en)
Other versions
ES2002089A4 (es
Inventor
Leone Gabriele Rotini
Egidio Marchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alfa Wasserman SpA
Original Assignee
Alfa Wasserman SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfa Wasserman SpA filed Critical Alfa Wasserman SpA
Publication of ES2002089A4 publication Critical patent/ES2002089A4/es
Application granted granted Critical
Publication of ES2002089T3 publication Critical patent/ES2002089T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

NUEVAS FORMULACIONES GALENICAS CON LIBERACION PROGRAMADA, PARA SER ADMINISTRADAS POR VIA ORAL, QUE CONTIENEN COMO INGREDIENTE ACTIVO UN COMPUESTO DOTADO DE ACTIVIDAD ANTIFLOGISTICA, ANALGESICA Y ANTIPIRETICA, COMO POR EJEMPLO UN ACIDO ARILACETICO O ARILPROPIONICO Y SUS SALES FARMACEUTICAMENTE ACEPTABLES. EN ESTAS NUEVAS FORMULACIONES, UNA PARTE DEL INGREDIENTE ACTIVO SE LIBERA EN UN CORTO PERIODO DE TIEMPO, DE MODO QUE EL MEDICAMENTO PUEDE DESARROLLAR RAPIDAMENTE SU ACCION TERAPEUTICA ALCANZANDO LOS NIVELS HEMATICOS NECESARIOS, MIENTRAS QUE LA PARTE RESTANTE DEL COMPONENTE ACTIVO SE LIBERA EN UN INTERVALO DE TIEMPO MAS LARGO, DE MODO QUE PERMITE LA COBERTURA TERAPEUTICA HASTA LA SIGUIENTE ADMINISTRACION. DICHA COBERTURA TERAPEUTICA PUEDE INCLUSO DURAR 24 HORAS; ASI, LAS NUEVAS FORMULACIONES FARMACEUTICAS OBJETO DE LA PRESENTE INVENCION SON ADECUADAS PARA UNA ADMINISTRACION DIARIA.
ES198787110389T 1986-07-23 1987-07-17 Nuevas formulaciones farmaceuticas con liberacion programada que contienen antiflogisticos. Expired - Lifetime ES2002089T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT03467/86A IT1200178B (it) 1986-07-23 1986-07-23 Formulazioni galeniche a cessione programmata contenenti farmaci ad attivita' antiflogistica

Publications (2)

Publication Number Publication Date
ES2002089A4 ES2002089A4 (es) 1988-07-16
ES2002089T3 true ES2002089T3 (es) 1993-11-16

Family

ID=11107923

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198787110389T Expired - Lifetime ES2002089T3 (es) 1986-07-23 1987-07-17 Nuevas formulaciones farmaceuticas con liberacion programada que contienen antiflogisticos.

Country Status (13)

Country Link
US (1) US4888178A (es)
EP (1) EP0255002B1 (es)
JP (1) JPH0774155B2 (es)
AT (1) ATE75604T1 (es)
DE (2) DE255002T1 (es)
DK (1) DK383987A (es)
ES (1) ES2002089T3 (es)
FI (1) FI92902C (es)
GR (1) GR3004509T3 (es)
IE (1) IE60220B1 (es)
IT (1) IT1200178B (es)
NO (1) NO174412C (es)
ZA (1) ZA874577B (es)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1215726B (it) * 1988-01-18 1990-02-22 Alfa Wassermann Spa Formulazioni galeniche a cessione programmata.
US5211957A (en) * 1988-03-25 1993-05-18 Ciba-Geigy Corporation Solid rapidly disintegrating dosage form
CH675537A5 (es) * 1988-03-25 1990-10-15 Ciba Geigy Ag
DE3822095A1 (de) * 1988-06-30 1990-01-04 Klinge Co Chem Pharm Fab Neue arzneimittelformulierung sowie verfahren zu deren herstellung
US5256699A (en) * 1988-10-18 1993-10-26 Ciba-Geify Corporation Dispersible tablet formulation of diclofenac acid free base
GB8824392D0 (en) 1988-10-18 1988-11-23 Ciba Geigy Ag Dispersible formulation
US4927639A (en) * 1989-02-02 1990-05-22 Warner-Lambert Company Modified release gemfibrozil composition
US4948581A (en) * 1989-02-17 1990-08-14 Dojin Iyaku-Kako Co., Ltd. Long acting diclofenac sodium preparation
US5368861A (en) * 1989-10-26 1994-11-29 Nippon Shinyaku Co., Ltd. Gastric preparation with sustained release
US5169645A (en) * 1989-10-31 1992-12-08 Duquesne University Of The Holy Ghost Directly compressible granules having improved flow properties
KR910011145A (ko) * 1989-12-14 1991-08-07 다니엘 에이. 스콜라 2세 향미를 오랫동안 지속적으로 방출하는 여러개의 캡슐로 싸여진 시스템을 갖는 압축된 당과류 정제
EP0437098A3 (en) * 1990-01-11 1991-09-18 Warner-Lambert Company Compressed confectionery tablets with at least two phases and sequential flavour delivery system
IE66933B1 (en) * 1990-01-15 1996-02-07 Elan Corp Plc Controlled absorption naproxen formulation for once-daily administration
US5198227A (en) * 1990-01-22 1993-03-30 Mcneil-Ppc, Inc. Dual subcoated simulated capsule medicament
JP2572673B2 (ja) * 1990-07-25 1997-01-16 エスエス製薬株式会社 徐放性錠剤
GB9022788D0 (en) * 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
JP2829794B2 (ja) * 1991-02-08 1998-12-02 エスエス製薬 株式会社 徐放性経口投与型プラノプロフェン製剤
US5464632C1 (en) * 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
FR2679451B1 (fr) * 1991-07-22 1994-09-09 Prographarm Laboratoires Comprime multiparticulaire a delitement rapide.
DE4140183C2 (de) * 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Retardform für ein Flurbiprofen enthaltendes Arzneimittel
DE4140184C2 (de) * 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Akutform für ein Flurbiprofen enthaltendes Arzneimittel
DE4140172C2 (de) * 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Retardform für ein Ibuprofen enthaltendes Arzneimittel
DE4140185C2 (de) * 1991-12-05 1996-02-01 Alfatec Pharma Gmbh Ein 2-Arylpropionsäurederivat in Nanosolform enthaltendes Arzneimittel und seine Herstellung
WO1993017673A1 (en) * 1992-03-03 1993-09-16 Top Gold Pty., Limited Sustained release analgesics
US5609884A (en) * 1992-08-31 1997-03-11 G. D. Searle & Co. Controlled release naproxen sodium plus naproxen combination tablet
IT1258143B (it) * 1992-09-11 1996-02-20 Alfa Wassermann Spa Compresse a cessione programmata contenenti naproxen
CA2128820A1 (en) * 1993-07-27 1995-01-28 Walter G. Gowan, Jr. Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6210714B1 (en) * 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
GB9325445D0 (en) 1993-12-13 1994-02-16 Cortecs Ltd Pharmaceutical formulations
US5830884A (en) * 1995-01-18 1998-11-03 National Starch And Chemical Investment Holding Corporation Pharmaceutical products containing thermally-inhibited starches
AU5200098A (en) * 1996-11-01 1998-05-29 Ilex Oncology, Inc. Sustained release formulation containing dfmo
US6312724B1 (en) 1997-04-04 2001-11-06 Isa Odidi Sustained release pharmaceutical matrix tablet of pharmaceutically acceptable salts of diclofenac and process for preparation thereof
FR2766089B1 (fr) * 1997-07-21 2000-06-02 Prographarm Lab Comprime multiparticulaire perfectionne a delitement rapide
AR017512A1 (es) * 1997-08-22 2001-09-12 Smithkline Beecham Corp Tabletas de metilcelulosa rapidamente desintegrables para administracion por via oral y procedimiento para prepararlas
AR016827A1 (es) 1997-08-22 2001-08-01 Smithkline Beecham Corp PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA
EP0898961A1 (de) * 1997-08-27 1999-03-03 Herta-Maria Dr. Sahlender Pharmazeutische Zubereitung zur verbesserten Schmerztherapie bei akutem, postoperativem oder chronischem Schmerz
US20030153623A1 (en) * 1998-07-22 2003-08-14 Yamanouchi Pharmaceutical Co., Ltd. Solid preparation containing sparingly soluble NSAIDs
US6153225A (en) * 1998-08-13 2000-11-28 Elan Pharma International Limited Injectable formulations of nanoparticulate naproxen
SE9802973D0 (sv) 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
US6165506A (en) * 1998-09-04 2000-12-26 Elan Pharma International Ltd. Solid dose form of nanoparticulate naproxen
US20060240105A1 (en) * 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
AU2012202743B2 (en) * 1998-11-02 2014-02-27 Alkermes Pharma Ireland Limited Multiparticulate modified release composition
EP1126826B3 (en) 1998-11-02 2019-05-15 Alkermes Pharma Ireland Limited Multiparticulate modified release composition of methylphenidate
US20070122481A1 (en) * 1998-11-02 2007-05-31 Elan Corporation Plc Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer
US20090297597A1 (en) * 1998-11-02 2009-12-03 Gary Liversidge Modified Release Ticlopidine Compositions
US20090149479A1 (en) * 1998-11-02 2009-06-11 Elan Pharma International Limited Dosing regimen
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
AU764453B2 (en) 1999-10-29 2003-08-21 Euro-Celtique S.A. Controlled release hydrocodone formulations
US6340471B1 (en) * 1999-12-30 2002-01-22 Alvin Kershman Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals
US6607748B1 (en) 2000-06-29 2003-08-19 Vincent Lenaerts Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
MXPA03003895A (es) 2000-10-30 2003-07-28 Euro Celtique Sa Formulaciones de hidrocodona de liberacion controlada.
DE10300325A1 (de) * 2003-01-09 2004-07-22 Hexal Ag Granulat mit öliger Substanz, Herstellungsverfahren und Tablette
US7344907B2 (en) * 2004-11-19 2008-03-18 International Business Machines Corporation Apparatus and methods for encapsulating microelectromechanical (MEM) devices on a wafer scale
US20060121112A1 (en) * 2004-12-08 2006-06-08 Elan Corporation, Plc Topiramate pharmaceutical composition
US20070298098A1 (en) * 2005-02-16 2007-12-27 Elan Pharma International Limited Controlled Release Compositions Comprising Levetiracetam
AU2006235483B2 (en) * 2005-04-12 2010-11-25 Elan Pharma International Limited Controlled release compositions comprising a cephalosporin for the treatment of a bacterial infection
JP4936420B2 (ja) * 2005-08-02 2012-05-23 塩野義製薬株式会社 徐放性顆粒剤
CA2696063C (en) 2007-08-15 2014-05-06 Mcneil-Ppc, Inc. Immediate release and sustained release ibuprofen dosing form
RU2462242C2 (ru) * 2007-08-15 2012-09-27 МакНЕЙЛ-ППС, ИНК. Режим дозирования ибупрофена с немедленным высвобождением и замедленным высвобождением
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
CA2771831C (en) * 2009-09-25 2018-03-06 Novartis Ag Oral pharmaceutical composition comprising diclofenac
WO2016174664A1 (en) 2015-04-29 2016-11-03 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
ES2954452T3 (es) * 2015-10-09 2023-11-22 Bayer Healthcare Llc Formulación de liberación modificada de naproxeno sódico
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
JP7163015B2 (ja) * 2016-10-31 2022-10-31 エスエス製薬株式会社 経口固形組成物
AU2018378348B2 (en) 2017-12-05 2024-09-19 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
CA3084953A1 (en) 2017-12-05 2019-06-13 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
CN110037994B (zh) * 2019-05-24 2022-04-12 中国药科大学 一种布洛芬速释缓释双层片及其制备方法
AU2020286441A1 (en) 2019-06-04 2022-01-06 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2793979A (en) * 1953-03-30 1957-05-28 Smith Kline French Lab Method of making a sustained release pharmaceutical tablet and product of the method
FR1159165A (fr) * 1953-11-03 1958-06-24 Smith Kline French Lab Comprimé pharmaceutique ou pilule et son procédé de fabrication
US3044938A (en) * 1955-07-01 1962-07-17 Sandoz Chemical Works Inc Sustained action pharmaceutical tablets
US3388041A (en) * 1964-01-27 1968-06-11 Richardson Merrell Inc High dosage sustained release tablet
US4012498A (en) * 1974-03-27 1977-03-15 Sandoz, Inc. Sustained release tablet formulations
US4167588A (en) * 1974-04-10 1979-09-11 Willard Miles J Preparation of fabricated baked potato product
JPS5661311A (en) * 1979-10-25 1981-05-26 Fujisawa Pharmaceut Co Ltd Thial amide or prolonged pharmaceutical preparation comprising its salt
DK151608C (da) * 1982-08-13 1988-06-20 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk peroralt polydepotpraeparat med kontrolleret afgivelse
JPS604120A (ja) * 1983-06-22 1985-01-10 Shionogi & Co Ltd 作用持続型ピナシジル製剤

Also Published As

Publication number Publication date
FI92902C (fi) 1995-01-25
ATE75604T1 (de) 1992-05-15
NO873072L (no) 1988-01-25
FI92902B (fi) 1994-10-14
JPS6354316A (ja) 1988-03-08
EP0255002B1 (en) 1992-05-06
GR3004509T3 (es) 1993-04-28
IE60220B1 (en) 1994-06-15
IT8603467A0 (it) 1986-07-23
NO873072D0 (no) 1987-07-22
IT1200178B (it) 1989-01-05
IE871981L (en) 1988-01-23
EP0255002A1 (en) 1988-02-03
DK383987D0 (da) 1987-07-22
NO174412C (no) 1994-05-04
DK383987A (da) 1988-01-24
ES2002089A4 (es) 1988-07-16
US4888178A (en) 1989-12-19
JPH0774155B2 (ja) 1995-08-09
DE3778781D1 (de) 1992-06-11
DE255002T1 (de) 1988-08-11
NO174412B (no) 1994-01-24
FI873225A0 (fi) 1987-07-22
FI873225A7 (fi) 1988-01-24
ZA874577B (en) 1988-01-19

Similar Documents

Publication Publication Date Title
ES2002089T3 (es) Nuevas formulaciones farmaceuticas con liberacion programada que contienen antiflogisticos.
ES2053702T3 (es) Nuevas formulas de galenica de accion programada.
ES2189803T3 (es) Procedimiento.
ES2058411T3 (es) Sustancia fr 901228 y su preparacion.
ES2079210T3 (es) Formulacion farmaceutica de aerosol.
ES2045153T3 (es) Metodo para la preparacion de formas de dosificacion de farmacos con liberacion sostenida que contienen hidroxi-propil-metilcelulosa y carboxilatos de metales alcalinos.
ES2063011T3 (es) Agentes antibacteriales de quinolonas y naftiridinas que contienen un alfa-aminoacido en la cadena lateral del 7-sustituyente.
PT97689A (pt) Processo para a preparacao de composicoes farmaceuticas incorporando como ingrediente activo isoxazol-4-carboxilamida e hidroxialquilideno-cianoacetamida
ES8307845A1 (es) Procedimiento para preparar una polilactida.
GT199700095A (es) Derivados 6,5-heterobiciclicos sustituidos.
PT91246A (pt) Processo para a preparacao de composicoes farmaceuticas para administracao endovenosa, contendo ciclosporina como ingrediente activo
AR003984A1 (es) Composiciones antipruriticas, cosmeticas y/o farmaceuticas, procedimiento para su preparacion y empleo de dichas composiciones para la obtencion de unmedicamento.
AR037592A1 (es) Formulaciones farmaceuticas de 5,7,14-triazatetraciclo (10.3.1.02,11.04,9)-hexadeca-2(11),3,5,7,9-pentaeno
FI94094B (fi) Kantajakoostumus kestovaikutteiselle lääkeainevalmisteelle
BR9401199A (pt) Preparados de medicamentos, processo para a preparação de um preparado de medicamento, processo para a preparação de uma formulação de medicamento.
PT95868A (pt) Processo para a prparacao de uma composicao de libertacao retardada que compreende acido polipropenoico e um medicamento activo, para tratamento de doencas periodonticas
AR013967A1 (es) UNA FORMULACION MEDICAMENTOSA PARA LA ADMINISTRACION ORAL DE PELLET DE DIFUSION CONTROLADA QUE TIENE LIBERACION CONTROLADA DE UN COMPUESTO ACTIVO QUE ES SELECCIONADO DEL ACIDO 1-CICLOPROPIL-7- [(S,S)-2,8-DIAZABICICLO [4.3.0] NON-8-IL ]-6-FLuOR-1,4-DIHIDRO-8-METOXI-4-OXO-3-QUINOLON CARBOXILICO O SALE
DK515489A (da) Dispergerbar laegemiddelformulering
ES2184145T3 (es) Compuestos de acido sulfonico o sulfonilamino-n-(heteroaralquil)-azaheterociclilamida.
ES2134237T3 (es) Composiciones farmaceuticas que contienen acido ursodesoxicolico.
BR9706214A (pt) Composições farmacêuticas de liberação controlada para administração oral contendo nifedipina como substância ativa e processo para a preparação de composiç es farmacêuticas para a administração oral contendo nifedipina como substância ativa
ES2077559T3 (es) Estabilizacion de proteinas terapeuticamente activas en preparados farmaceuticos.
ES2118726T3 (es) Factor de crecimiento epidermal como medicamento para la restauracion de neuronas de la substantia nigra en el tratamiento de trastornos neurodegenerativos.
AR013261A1 (es) Formulaciones farmaceuticas para analogos de camptotecina en capsula de gelatina
MX9207171A (es) Preparaciones farmaceuticas a liberacion programada.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 255002

Country of ref document: ES